Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Lenalidomide Maintenance After Salvage Therapy in Relapsed/Refractory Non-Hodgkin T-cell Lymphoma
KCT0003593Phase 2Recruiting
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in T-cell lymphoma, sponsored by Samyang Biopharmaceuticals Corporation. Started Feb 2019; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on KCT0003593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003593.